Pharma Giant Lonza Sells Capsules Division to UK Firm for CHF 2.3 Billion

Basel’s pharmaceutical titan Lonza has pulled the trigger on a massive strategic divestment, selling its Capsules and Health Ingredients (CHI) division to British private equity firm Lone Star Funds. The deal, valued at a staggering CHF 2.3 billion ($3 billion), marks a decisive shift in the Swiss company's operational focus. Lonza is set to receive an immediate cash injection of CHF 1.7 billion, a liquidity boost that underscores the magnitude of this transaction. Expected to close in the second half of 2026, this sale is not merely a trimming of fat; it is a fundamental restructuring of one of Switzerland's most important industrial players.

While Lonza hands over operational control, it is not severing ties completely. The company will retain a significant 40% stake in the business, ensuring it keeps a foot in the door of the lucrative capsules market. This hybrid exit strategy allows Lonza to monetize the asset immediately while maintaining a preferential right on any future sale, potentially driving the total gain from the division to over CHF 3 billion. The move signals to the market that Lonza is agile, decisive, and ready to sacrifice legacy divisions to streamline its future.

This is the final piece of the puzzle: with this sale, Lonza completes its aggressive metamorphosis into a pure-play Contract Development and Manufacturing Organisation (CDMO). The era of hybrid operations is over. The company has explicitly stated that the CHF 1.7 billion cash windfall will not sit idle. Instead, it will be deployed rapidly to finance organic growth and fund targeted acquisitions. Lonza is doubling down on its core competency—developing and manufacturing drugs for other pharmaceutical companies—and is using this capital to fortify its technological and industrial capacities.

By shedding the CHI division, Lonza frees itself to focus entirely on the high-margin, high-complexity world of CDMO services. This sector demands relentless innovation and massive capital expenditure, both of which are now secured by this sale. The strategy is clear: dominate the global supply chain for biopharmaceuticals. While competitors grapple with diversified portfolios, Lonza is streamlining its operations to become the undisputed heavyweight champion of drug manufacturing.

Investors have immediate cause for celebration as Lonza prepares to unleash a significant portion of the deal's proceeds directly back to them. Upon receipt of the initial payment, the company plans to launch a share buyback program worth CHF 500 million. This move demonstrates confidence in the company's valuation and a commitment to shareholder returns, even as it navigates a complex corporate restructuring.

The distribution of half a billion francs serves as a sweetener for investors who have watched the company navigate the volatile post-pandemic pharmaceutical landscape. It balances the long-term reinvestment strategy with immediate financial gratification. However, this payout is just one component of the financial picture. The total value extraction from the CHI division—including the upfront cash, the retained stake, and future performance—is projected to surpass CHF 3 billion, a figure that validates the management's decision to sell at this specific juncture.

Despite the influx of cash, the transaction comes with a stinging accounting reality. Lonza is forecasting an exceptional non-cash impairment loss of approximately CHF 1.3 billion. This massive write-down, largely attributable to goodwill associated with the CHI assets, will impact the company's reported figures when the 2025 results are published on April 1, 2026. It is a heavy price to pay on paper, but one that management deems necessary to clear the decks for the future.

The CHI division will now be classified as a "discontinued operation," a technical label that marks the end of an era for the Visp and Basel operations associated with capsule production. Yet, by retaining a 40% stake, Lonza hedges its bets. If Lone Star Funds succeeds in optimizing the business, Lonza shares in the upside without bearing the operational burden. It is a calculated risk: accept a short-term accounting hit to secure a leaner, more profitable future focused exclusively on the booming CDMO market.